GILD submits NDA for “TAF-Stribild” (i.e. Stribild with TAF substituting for Viread): http://finance.yahoo.com/news/gilead-submits-drug-application-u-133000911.html The European MAA will be submitted later this quarter, according to the PR. The commercial uptake of TAF is the biggest single risk for GILD investors, IMO (#msg-107185965, #msg-106583794, #msg-106586262).